Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s stock price has plunge by 5.34%relation to previous closing price of $2.81. Nevertheless, the company has seen a 20.82% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-08 that NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) of a class action securities lawsuit.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
RCKT has 36-month beta value of 0.62. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for RCKT is 99.77M, and currently, short sellers hold a 14.07% ratio of that float. The average trading volume of RCKT on July 09, 2025 was 5.12M shares.
RCKT’s Market Performance
RCKT’s stock has seen a 20.82% increase for the week, with a 6.86% rise in the past month and a -42.19% fall in the past quarter. The volatility ratio for the week is 8.67%, and the volatility levels for the past 30 days are at 8.45% for Rocket Pharmaceuticals Inc The simple moving average for the past 20 days is 5.53% for RCKT’s stock, with a -71.23% simple moving average for the past 200 days.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with Evercore ISI repeating the rating for RCKT by listing it as a “In-line.” The predicted price for RCKT in the upcoming period, according to Evercore ISI is $5 based on the research report published on May 30, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $7. The rating they have provided for RCKT stocks is “Equal-Weight” according to the report published on May 28th, 2025.
Leerink Partners gave a rating of “Market Perform” to RCKT, setting the target price at $8 in the report published on May 28th of the current year.
RCKT Trading at -34.57% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.03% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Ondrey Aaron, who sale 1,477 shares at the price of $2.88 back on Jul 03 ’25. After this action, Ondrey Aaron now owns 128,173 shares of Rocket Pharmaceuticals Inc, valued at $4,257 using the latest closing price.
Stock Fundamentals for RCKT
The total capital return value is set at -0.62. Equity return is now at value -60.45, with -53.17 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -8.23. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -143.2.
Currently, EBITDA for the company is -273.2 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.19.
Conclusion
To put it simply, Rocket Pharmaceuticals Inc (RCKT) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
